

PRO-URGENCY is an exclusive formulation of 10 complementary and clinically proven probiotic cultures. It's one of the most powerful probiotic formulas for complete re-establishment of intestinal flora, or complete restart, for the treatment of diseases such as irritable bowel syndrome (IBS), diarrhoea, constipation and colitis, or for post-antibiotic use. The maintenance of intestinal flora is very important in order to maximize the absorption of nutrients, vitamins and electrolytes.

This group of gram-positive probiotic bacteria facilitates the elimination of pathogenic bacteria (like *E. Coli*) and viruses, decreases toxins such as ammonia from nitrogen digestion for protein synthesis, and improves immune system function (80% of immune system function originates in the intestines), preventing many serious diseases.

Irritable bowel syndrome is a gastrointestinal problem which, in developed countries, affects up to 15% of adults and can be caused by the consumption of alcohol, caffeinated drinks or diuretics, soft drinks and medications including antibiotics. Stress can also compromise the efficacy of the digestive tract by increasing the production of hydrochloric acid (HCl). The symptoms of this disease include bloating, cramping and abdominal pain and in extreme conditions, diarrhoea and constipation.

New Roots Europe has developed this unique formulation of 100 billion CFU (2 capsules) to restore the microbial balance necessary for good general health. The enteric coating of the capsules protects the product from gastric juices and ensures its strength 100%.

**Ingredients:** Potato starch, bacterial culture (50 billion live active, healthy cells per capsule, see nutritional information), inulin (from chicory root, *Cichorium intybus*), arabinogalactan (from *Larix laricina*), anticaking agent: magnesium salts of fatty acids, L-ascorbic acid (vitamin C), GPS™ enteric coated vegetable capsule (glazing agent: hydroxypropylmethylcellulose; aqueous enteric-coating solution; purified water).

#### Nutritional information:

2 enteric capsules (1 273 mg)

#### Size and format:

30 enteric-coated vegetable capsules

##### Human strains

<i>Bifidobacterium longum ssp. longum</i> UB7691	18 billion CFU
<i>Lactobacillus casei</i> UB1499	18 billion CFU
<i>Lactobacillus rhamnosus</i> UB5115	18 billion CFU
<i>Lactobacillus acidophilus</i> UB5997	2 billion CFU
<i>Bifidobacterium bifidum</i> UB4280	2 billion CFU
<i>Bifidobacterium breve</i> UB8674	2 billion CFU
<i>Bifidobacterium longum ssp. infantis</i> UB9214	2 billion CFU

##### Plant strains

<i>Lactobacillus plantarum</i> UB2783	18 billion CFU
---------------------------------------	----------------

##### Dairy strains

<i>Lactobacillus helveticus</i> UB7229	18 billion CFU
<i>Lactobacillus paracasei</i> UB1978	2 billion CFU
Inulin	30 mg
Arabinogalactan (AOS)	30 mg
Vitamin C (L-ascorbic acid)	12 mg (15%*)

#### Recommended daily dose:

2 capsules daily. If you are taking antibiotics, take this product at least 2-3 hours before or after taking them.

Do not exceed the stated recommended daily dose.

Store preferably refrigerated.

CFU: Colony-Forming Unit Cells \*NRV: Nutrient Reference Value in %.

**GPS™ enteric coating: Protects contents from stomach acids and delivers 100% potency to the intestines.**

#### Indications and uses:

Acute conditions:

- Antibiotic-associated diarrhoea
- Acute infectious diarrhoea

Cardiovascular diseases  
Stress and depression

#### Cautions:

Consult a health-care practitioner before using if you have fever, vomiting, bloody diarrhoea, or severe abdominal pain. Discontinue use if symptoms of digestive upset (diarrhoea) persist or worsen beyond 3 days. Consult a health-care practitioner if you have an immune-compromised condition (e.g. lymphoma or AIDS).

***BIFIDOBACTERIUM LONGUM*, *B. BIFIDUM*, *B. INFANTIS* and *B. BREVE*:** The four strains of *Bifidobacterium* in PRO-URGENCY are among the most important probiotic species to implement themselves in the gastrointestinal tract at birth and then maintain good health during adult life. These bacteria represent 95% of the intestinal flora of new-borns and decrease to 25% in adults<sup>(1)</sup>.

***BIFIDOBACTERIUM LONGUM* ssp. *LONGUM*:** this product contains the UB7691 human strain. A protein factor produced by *B. longum* inhibits the adhesion of the enterotoxigenic strain of *Escherichia coli*.<sup>(2)</sup> It has anti-inflammatory properties and is indicated for gastrointestinal disorders such as ulcerative colitis<sup>(3)</sup>, antibiotic-associated diarrhoea<sup>(4,5)</sup>, Irritable Bowel Syndrome<sup>(6)</sup>, and seasonal allergies<sup>(7,8)</sup>. It helps in the formation of lactic acid and formic acid, lowering intestinal pH and preventing the proliferation of harmful bacteria<sup>(9)</sup>. It is also a significant producer of B vitamin<sup>(10)</sup>.

***BIFIDOBACTERIUM BIFIDUM*:** this product contains the UB4280 human strain. They are found in the mucosal lining of the last part of the small bowel and are the predominant strains that colonise the large bowel and support bowel health, hygiene, and functionality. They reduce serum cholesterol and dissolve bile salts<sup>(11,12)</sup>. *B. bifidum* has been shown to exert antibacterial activity against *Helicobacter pylori*<sup>(13,14)</sup>, reduces apoptosis in the intestinal epithelium of children with necrotising enterocolitis<sup>(15)</sup>, regulates the immune system response<sup>(16-18)</sup>, reduces the duration and severity of colds<sup>(17)</sup>, provides anti-inflammatory activity in chronic diseases of the large bowel (e.g., irritable bowel syndrome)<sup>(19,20)</sup> and reduces the incidence of radiotherapy-induced diarrhoea in cervical cancer patients<sup>(21)</sup>.

***BIFIDOBACTERIUM BREVE*:** this product contains the UB8674 human strain. It maintains colon homeostasis by reducing inflammation through induction of intestinal IL-10 producing Tr1 cells<sup>(22)</sup>. It protects colon function, relieves constipation, and reduces gas, bloating, and diarrhoea<sup>(22,23)</sup>. It improves ulcerative colitis symptoms<sup>(24)</sup>. In addition, it stimulates the immune system<sup>(23,25)</sup>, inhibits *Escherichia coli*<sup>(26)</sup> and suppresses *the Candida fungus*<sup>(27)</sup>. It reduces fat, liver function, and systemic inflammation in people prone to obesity<sup>(28)</sup>. In neonates, it improves gastrointestinal problems by stabilising the intestinal flora<sup>(29)</sup> and reduces the incidence of necrotising enterocolitis<sup>(30)</sup>. In children with coeliac disease, it reduces the pro-inflammatory cytokine TNF-alpha<sup>(31)</sup>. It improves adverse effects, such as fever, infections, and intestinal disorders, in chemotherapy patients<sup>(32)</sup>.

***BIFIDOBACTERIUM LONGUM* ssp. *INFANTIS*:** this product contains the UB9214 human strain. It is the dominant probiotic inhabiting the distal part of the small bowel and colon. It is one of the first species to colonise the infant intestinal tract<sup>(33)</sup> and is critical in adults for intestinal health and immune system function<sup>(34)</sup>. It is extremely good at surviving stomach and bile acids<sup>(35)</sup>, and is generally able to adhere to intestinal tissue<sup>(36)</sup>. It produces acetic acid and inhibits pathogenic bacteria<sup>(37)</sup>. It produces bacteriocins, which act against *Salmonella*, *Shigella*, and *E. coli*<sup>(38,39)</sup>. It relieves many symptoms of Irritable Bowel Syndrome (IBS), such as pain, bloating, normalises bowel movements, and regulates the IL-10/IL-12 ratio<sup>(40-42)</sup>. It reduces systemic pro-inflammatory biomarkers in chronic inflammatory diseases such as ulcerative colitis, chronic fatigue syndrome, and psoriasis, demonstrating that the immunomodulatory effects of the microbiota are not limited to the mucosa but encompass the systemic immune system<sup>(43)</sup>. It can relieve the symptoms of untreated coeliac disease<sup>(44)</sup>.

***LACTOBACILLUS CASEI*:** this product contains the UB1499 human strain. It reduces the duration and incidence of infections such as bronchitis, pneumonia and rhinopharyngitis<sup>(45-47)</sup>. Regarding intestinal infections, it boosts immunity against bacterial infections (e.g., *Escherichia coli*) and viral infections (e.g., influenza vaccinations)<sup>(48-51)</sup>. In children, it improves allergic rhinitis symptoms<sup>(52)</sup>, helps eradicate *Helicobacter pylori* in combination with antibiotic therapy<sup>(53)</sup>, is effective against viral diarrhoea<sup>(54)</sup> and improves the general incidence of infections<sup>(55)</sup>.

***LACTOBACILLUS RHAMNOSUS*:** this product contains the UB5115 human strain. It is one of the most widely researched probiotic species due to its tolerance to acidic conditions. It colonises in the intestinal membranes, providing numerous health benefits: it increases lactic acid production, actively suppressing the growth of harmful bacteria such as *Salmonella*<sup>(56)</sup>; it is effective in preventing antibiotic-associated diarrhoea<sup>(57)</sup> and *Clostridium difficile*-associated diarrhoea<sup>(58)</sup>. It strengthens the immune system and is a good co-adjuvant for the influenza vaccine<sup>(59)</sup>; it improves intestinal barrier function for the relief of autoimmune diseases such as arthritis<sup>(60)</sup> and allergies<sup>(61)</sup>. It improves the blood lipid profile<sup>(62)</sup> and reduces cholesterol<sup>(63)</sup>. It may prevent or relieve symptoms of postpartum depression and anxiety<sup>(64)</sup>, regenerate the vaginal flora in women by reducing colonisation by oral bacteria and fungi<sup>(65)</sup>, and may reduce the prevalence of gestational diabetes mellitus<sup>(66)</sup>. In children, it reduces the frequency and duration of diarrhoea and vomiting<sup>(67)</sup>, rotavirus diarrhoea<sup>(68)</sup>, and antibiotic-associated diarrhoea<sup>(69)</sup>. It reduces the incidence of atopic dermatitis<sup>(70,71)</sup>. Drinking milk supplemented with *L. rhamnosus* reduces the risk of tooth decay in children<sup>(72)</sup>.

***LACTOBACILLUS ACIDOPHILUS*:** this product contains the UB5997 human strain. It improves the general symptoms of patients with Irritable Bowel Syndrome<sup>(73)</sup>. It helps maintain an acidic environment in the intestinal tract by preventing the growth of harmful bacteria and reduces antibiotic-associated diarrhoea<sup>(74)</sup>. It reduces total plasma cholesterol and low-density

lipoprotein (LDL) cholesterol<sup>(75,76)</sup>. It helps improve digestive health by maintaining the intestinal barrier, restoring intestinal flora, improving digestion, reinforcing the immune system, and supporting beneficial bacteria that thrive in the colon<sup>(77)</sup>. It helps improve symptoms of allergic rhinitis<sup>(78)</sup>, hay fever<sup>(79)</sup> and atopic dermatitis<sup>(80)</sup>. When used in combination with *B. bifidum*, it reduces the incidence of radiotherapy-induced diarrhoea in cervical cancer patients<sup>(81)</sup>.

**LACTOBACILLUS PLANTARUM:** this product contains the UB2783 plant strain. It acts against unwanted bacteria by improving the symptoms of Irritable Bowel Syndrome such as excessive gas, bloating and abdominal discomfort<sup>(82-86)</sup>, as well as in ulcerative colitis<sup>(87,88)</sup>. It regulates immune response and is beneficial in the treatment of atopic dermatitis in children<sup>(89)</sup>. It has immunostimulatory effects in the elderly, reducing the number of infections<sup>(90)</sup>. It improves gastrointestinal symptoms during antibiotic therapy<sup>(91)</sup>. It reduces cardiovascular risk factors and may be useful as a protective agent in the primary prevention of atherosclerosis in smokers<sup>(92)</sup>. In adults with hypercholesterolemia, it lowers cholesterol and high blood pressure, which may thus reduce the risk of cardiovascular diseases<sup>(93)</sup>. It improves symptoms of lactose intolerance, such as diarrhoea and flatulence in combination with another probiotic<sup>(94)</sup>. Together with other *Lactobacillus* species, it can restore the vaginal flora by improving the pH and diagnosis of bacterial vaginosis when administered orally<sup>(95)</sup>.

**LACTOBACILLUS HELVETICUS:** this product contains the UB7229 dairy strain. It protects the gastrointestinal tract, strengthening the systemic humoral and intestinal mucosal immune response in elite athletes<sup>(96)</sup>. It has been shown to cause an antidepressant effect in animals, probably due to the microbiota-gut-brain axis connection<sup>(97)</sup>. Fermented milk with *L. helveticus* improves cognitive function<sup>(98)</sup> and lowers blood pressure<sup>(99)</sup>. In animals, it increases bone density and bone mineral content<sup>(100)</sup>, in postmenopausal women it has a positive effect on calcium metabolism<sup>(101)</sup>. It controls unwanted intestinal micro-organisms and bacteria (*Salmonella enteritidis*, *Campylobacter jejuni*, *Escherichia coli*, *Candida albicans*, etc.), regulates immune response and reduces lactose intolerance<sup>(102)</sup>.

**LACTOBACILLUS PARACASEI:** this product contains the UB1978 dairy strain. It significantly enhances the specific immune response in healthy people who have received the influenza vaccine<sup>(103)</sup>. It improves digestive function<sup>(104)</sup> and symptoms (especially eye symptoms) in patients with allergic rhinitis treated with oral antihistamines<sup>(105)</sup>. It is also useful against *Staphylococcus aureus*, *Escherichia coli*, and *Salmonella* infections<sup>(106-108)</sup>. It relieves the frequency and duration of acute diarrhoea in children<sup>(109)</sup>. It improves neurocognitive function in patients with chronic fatigue syndrome when used in combination with other probiotics<sup>(110)</sup>.

**INULIN:** It is a fructooligosaccharide (FOS) of plant origin, extracted from the root of chicory (*Cichorium intybus*). It acts as a prebiotic, creating the right environment for probiotics or beneficial micro-organisms to reproduce faster and in greater numbers<sup>(111-113)</sup>. It increases the population of *Bifidobacterium* probiotics in the colon and reduces toxic metabolites and harmful enzymes. It prevents pathogenic and autogenous diarrhoea and constipation and protects liver function<sup>(114)</sup>.

**ARABINOGALACTAN:** it is an arabino-oligosaccharide (AOS) of plant origin from the larch tree (*Larix laricina*). It is an excellent prebiotic that increases the production of short-chain fatty acids (mainly butyrate), which acts as an energy substrate for the epithelial cells of the colon and protects the intestinal mucosa. It activates the immune response and selectively stimulates the growth and activity of probiotic bacteria<sup>(115)</sup>. It is useful in fighting infections due to its ability to decrease bacterial adherence<sup>(116,117)</sup>. In addition, it lowers the intestinal pH and improves mineral absorption<sup>(117-120)</sup>.

## References:

- 1) Femia, Angelo Pietro, et al. "Antitumorogenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics *Lactobacillus rhamnosus* and *Bifidobacterium lactis* on azoxymethane-induced colon carcinogenesis in rats." *Carcinogenesis* 23.11 (2002): 1953-1960.
- 2) Fujiwara, Shigeru, et al. "Proteinaceous factor (s) in culture supernatant fluids of bifidobacteria which prevents the binding of enterotoxigenic *Escherichia coli* to ganglioside GM1." *Applied and environmental microbiology* 63.2 (1997): 506-512.
- 3) Furrer, Elizabeth, et al. "Synbiotic therapy (*Bifidobacterium longum*/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial." *Gut* 54.2 (2005): 242-249.
- 4) Orrhage, K., B. Brismar, and C. E. Nord. "Effect of supplements with *Bifidobacterium longum* and *Lactobacillus acidophilus* on the intestinal microbiota during administration of clindamycin." *Microbial Ecology in Health and Disease* 7.1 (1994): 17-25.
- 5) Koning, Catherina JM, et al. "The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxicillin." *The American journal of gastroenterology* 103.1 (2008): 178-189.
- 6) Ortiz-Lucas, María, et al. "Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis." *Rev Esp Enferm Dig* 105.1 (2013): 19-36.
- 7) Xiao, Jin-zhong, et al. "Clinical efficacy of probiotic *Bifidobacterium longum* for the treatment of symptoms of Japanese cedar pollen allergy in subjects evaluated in an environmental exposure unit." *Allergology international* 56.1 (2007): 67-75.
- 8) Takahashi, N., et al. "Immunostimulatory oligodeoxynucleotide from *Bifidobacterium longum* suppresses Th2 immune responses in a murine model." *Clinical & Experimental Immunology* 145.1 (2006): 130-138.
- 9) Makras, Lefteris, and Luc De Vuyst. "The in vitro inhibition of Gram-negative pathogenic bacteria by bifidobacteria is caused by the production of organic acids." *International Dairy Journal* 16.9 (2006): 1049-1057.
- 10) LeBlanc, J. G., et al. "B-Group vitamin production by lactic acid bacteria—current knowledge and potential applications." *Journal of Applied Microbiology* 111.6 (2011): 1297-1309.
- 11) Klaver, F. A., and Roelof Van Der Meer. "The assumed assimilation of cholesterol by *Lactobacilli* and *Bifidobacterium bifidum* is due to their bile salt-deconjugating activity." *Applied and Environmental Microbiology* 59.4 (1993): 1120-1124.
- 12) Zanotti, Ilaria, et al. "Evidence for cholesterol-lowering activity by *Bifidobacterium bifidum* PRL2010 through gut microbiota modulation." *Applied microbiology and biotechnology* 99.16 (2015): 6813-6829.
- 13) Shirasawa, Y., et al. "*Bifidobacterium bifidum* BF-1 suppresses *Helicobacter pylori*-induced genes in human epithelial cells." *Journal of dairy science* 93.10 (2010): 4526-4534.
- 14) Chenoll, E., et al. "Novel probiotic *Bifidobacterium bifidum* CECT 7366 strain active against the pathogenic bacterium *Helicobacter pylori*." *Applied and environmental microbiology* 77.4 (2011): 1335-1343.
- 15) Khailova, Ludmila, et al. "*Bifidobacterium bifidum* reduces apoptosis in the intestinal epithelium in necrotizing enterocolitis." *American Journal of Physiology-Gastrointestinal and Liver Physiology* 299.5 (2010): G1118-G1127.
- 16) Fu, Yu-Rong, et al. "Effects of *Bifidobacterium bifidum* on adaptive immune senescence in aging mice." *Microbiology and immunology* 54.10 (2010): 578-583.
- 17) De Vrese, Michael, et al. "Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial." *Vaccine* 24.44 (2006): 6670-6674.
- 18) Park, Ji-Hee, et al. "Encapsulated *Bifidobacterium bifidum* potentiates intestinal IgA production." *Cellular immunology* 219.1 (2002): 22-27.
- 19) Guglielmetti, Simone, et al. "Randomised clinical trial: *Bifidobacterium bifidum* MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study." *Alimentary pharmacology & therapeutics* 33.10 (2011): 1123-1132.
- 20) Kim, Namju, et al. "Oral feeding of *Bifidobacterium bifidum* (BGN4) Prevents CD4+ CD45RB high T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation." *Clinical Immunology* 123.1 (2007): 30-39.
- 21) Chitapanarux, Imjai, et al. "Randomized controlled trial of live *Lactobacillus acidophilus* plus *Bifidobacterium bifidum* in prophylaxis of diarrhea during radiotherapy in cervical cancer patients." *Radiation Oncology* 5.1 (2010): 31.
- 22) Jeon, Seong Gyu, et al. "Probiotic *Bifidobacterium breve* induces IL-10-producing Tr1 cells in the colon." *PLoS pathogens* 8.5 (2012): e1002714.
- 23) Tabbers, M. M., et al. "Is *Bifidobacterium breve* effective in the treatment of childhood constipation? Results from a pilot study." *Nutrition journal* 10.1 (2011): 19.
- 24) Ishikawa, Hideki, et al. "Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study." *Digestion* 84.2 (2011): 128-133.
- 25) Mullié, Catherine, et al. "Increased poliovirus-specific intestinal antibody response coincides with promotion of *Bifidobacterium longum-infantis* and *Bifidobacterium breve* in infants: a randomized, double-blind, placebo-controlled trial." *Pediatric research* 56.5 (2004): 791-795.
- 26) Sheehan, Vivien M., et al. "Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain *Bifidobacterium breve* UCC2003." *Microbiology* 153.10 (2007): 3563-3571.
- 27) Mendonça, Fabio Henrique Boarini Pacheco, et al. "Effects of probiotic bacteria on *Candida* presence and IgA anti-*Candida* in the oral cavity of elderly." *Brazilian dental journal* 23.5 (2012): 534-538.
- 28) Minami, Jun-ichi, et al. "Oral administration of *Bifidobacterium breve* B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial." *Journal of nutritional science* 4 (2015).
- 29) Kitajima, Hiroyuki, et al. "Early administration of *Bifidobacterium breve* to preterm infants: randomised controlled trial." *Archives of Disease in Childhood-Fetal and Neonatal Edition* 76.2 (1997): F101-F107.
- 30) Braga, Tacianna Duque, et al. "Efficacy of *Bifidobacterium breve* and *Lactobacillus casei* oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial—." *The American journal of clinical nutrition* 93.1 (2010): 81-86.
- 31) Klemenak, Martina, et al. "Administration of *Bifidobacterium breve* Decreases the Production of TNF- $\alpha$  in Children with Celiac Disease." *Digestive diseases and sciences* 60.11 (2015): 3386-3392.
- 32) Wada, Mariko, et al. "Effects of the enteral administration of *Bifidobacterium breve* on patients undergoing chemotherapy for pediatric malignancies." *Supportive care in cancer* 18.6 (2010): 751-759.
- 33) He, Fang, et al. "Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants." *Pathogens and Disease* 30.1 (2001): 43-47.
- 34) Ishibashi, N., T. Yaeshima, and H. Hayasawa. "Bifidobacteria: their significance in human intestinal health." *Malaysian Journal of Nutrition* 3.2 (1997): 149-159.
- 35) Sun, Wenrong, and Mansel W. Griffiths. "Survival of bifidobacteria in yogurt and simulated gastric juice following immobilization in gellan-xanthan beads." *International Journal of Food Microbiology* 61.1 (2000): 17-25.
- 36) Bernet, Marie-Francoise, et al. "Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions." *Applied and environmental microbiology* 59.12 (1993): 4121-4128.
- 37) Gibson, G. R., and Xin Wang. "Regulatory effects of bifidobacteria on the growth of other colonic bacteria." *Journal of Applied Microbiology* 77.4 (1994): 412-420.
- 38) Cheikhoussef, Ahmad, et al. "Antimicrobial activity and partial characterization of bacteriocin-like inhibitory substances (BLIS) produced by *Bifidobacterium infantis* BCRC 14602." *Food Control* 20.6 (2009): 553-559.
- 39) Cheikhoussef, Ahmad, et al. "Bifidin I—a new bacteriocin produced by *Bifidobacterium infantis* BCRC 14602: Purification and partial amino acid sequence." *Food Control* 21.5 (2010): 746-753.
- 40) Whorwell, Peter J., et al. "Efficacy of an encapsulated probiotic *Bifidobacterium infantis* 35624 in women with irritable bowel syndrome." *The American journal of gastroenterology* 101.7 (2006): 1581-1590.
- 41) Brenner, Darren M., and William D. Chey. "*Bifidobacterium infantis* 35624: a novel probiotic for the treatment of irritable bowel syndrome." *Reviews in gastroenterological disorders* 9.1 (2009): 7-15.

- 42) O'Mahony, Liam, et al. "Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles." *Gastroenterology* 128.3 (2005): 541-551.
- 43) Groeger, David, et al. "Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut." *Gut microbes* 4.4 (2013): 325-339.
- 44) Smecoul, Edgardo, et al. "Exploratory, randomized, double-blind, placebo-controlled study on the effects of *Bifidobacterium infantis* naten life start strain super strain in active celiac disease." *Journal of clinical gastroenterology* 47.2 (2013): 139-147.
- 45) Guillemard, E., et al. "Consumption of a fermented dairy product containing the probiotic *Lactobacillus casei* DN-114 001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial." *British journal of nutrition* 103.1 (2010): 58-68.
- 46) Cobo Sanz, JMa, J. A. Mateos, and A. Muñoz Conejo. "Efecto de *Lactobacillus casei* sobre la incidencia de procesos infecciosos en niños/as." *Nutrición Hospitalaria* 21.4 (2006): 547-551.
- 47) Turchet, P., et al. "Effect of fermented milk containing the probiotic *Lactobacillus casei* DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study." *The journal of nutrition, health & aging* 7.2 (2003): 75-77.
- 48) Isolauri, Erika, et al. "Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by *Lactobacillus casei* GG." *Vaccine* 13.3 (1995): 310-312.
- 49) Matsuzaki, T., et al. "The effect of oral feeding of *Lactobacillus casei* strain Shirota on immunoglobulin E production in mice." *Journal of Dairy Science* 81.1 (1998): 48-53.
- 50) Ingrassia, Isabelle, Antony Leplingard, and Arlette Darfeuille-Michaud. "*Lactobacillus casei* DN-114 001 inhibits the ability of adherent-invasive *Escherichia coli* isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells." *Applied and environmental microbiology* 71.6 (2005): 2880-2887.
- 51) Boge, Thierry, et al. "A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials." *Vaccine* 27.41 (2009): 5677-5684.
- 52) Giovannini, Marcello, et al. "A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing *Lactobacillus casei* in pre-school children with allergic asthma and/or rhinitis." *Pediatric research* 62.2 (2007): 215-220.
- 53) Sýkora, Josef, et al. "Effects of a specially designed fermented milk product containing probiotic *Lactobacillus casei* DN-114 001 and the eradication of *H. pylori* in children: a prospective randomized double-blind study." *Journal of clinical gastroenterology* 39.8 (2005): 692-698.
- 54) Guarino, Alfredo, et al. "Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea." *Journal of pediatric gastroenterology and nutrition* 25.5 (1997): 516-519.
- 55) Merenstein, D., et al. "Use of a fermented dairy probiotic drink containing *Lactobacillus casei* (DN-114 001) to decrease the rate of illness in kids: the DRINK study A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial." *European journal of clinical nutrition* 64.7 (2010): 669-677.
- 56) De Keersmaecker, Sigrid CJ, et al. "Strong antimicrobial activity of *Lactobacillus rhamnosus* GG against *Salmonella typhimurium* is due to accumulation of lactic acid." *FEMS microbiology letters* 259.1 (2006): 89-96.
- 57) Szajewska, H., and M. Kołodziej. "Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG in the prevention of antibiotic-associated diarrhoea in children and adults." *Alimentary pharmacology & therapeutics* 42.10 (2015): 1149-1157.
- 58) Goldenberg, Joshua Z., et al. "Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children." *The Cochrane Library* (2013).
- 59) Davidson, Lisa E., et al. "*Lactobacillus* GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial." *European journal of clinical nutrition* 65.4 (2011): 501-507.
- 60) Baharav, Ehud, et al. "*Lactobacillus* GG bacteria ameliorate arthritis in Lewis rats." *The Journal of nutrition* 134.8 (2004): 1964-1969.
- 61) Thomas, Debra J., et al. "*Lactobacillus rhamnosus* HN001 attenuates allergy development in a pig model." *PLoS One* 6.2 (2011): e16577.
- 62) Kekkonen, Riina A., et al. "Effect of probiotic *Lactobacillus rhamnosus* GG intervention on global serum lipidomic profiles in healthy adults." *World journal of gastroenterology: WJG* 14.20 (2008): 3188.
- 63) Costabile, Adele, et al. "Effect of soluble corn fibre with *Lactobacillus rhamnosus* GG and the pilus-deficient derivative GG-PB12 on faecal microbiota, immune function and metabolism in healthy elderly (Saimes study)." *Frontiers in Immunology* 8 (2017): 1443.
- 64) Slykerman, R. F., et al. "Effect of *Lactobacillus rhamnosus* HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomized double-blind placebo-controlled trial." *EBio- Medicine* 24 (2017): 159-165.
- 65) Reid, Gregor, et al. "Oral use of *Lactobacillus rhamnosus* GR-1 and *L. fermentum* RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women." *Pathogens and Disease* 35.2 (2003): 131-134.
- 66) Wickens, Kristin L., et al. "Early pregnancy probiotic supplementation with *Lactobacillus rhamnosus* HN001 may reduce the prevalence of gestational diabetes mellitus: a randomized controlled trial." *British Journal of Nutrition* 117.6 (2017): 804-813.
- 67) Basu, Sriparna, et al. "Effect of *Lactobacillus rhamnosus* GG in persistent diarrhea in Indian children: a randomized controlled trial." *Journal of clinical gastroenterology* 41.8 (2007): 756-760.
- 68) Szymanski, H., et al. "Treatment of acute infectious diarrhoea in infants and children with a mixture of three *Lactobacillus rhamnosus* strains—a randomized, double-blind, placebo-controlled trial." *Alimentary pharmacology & therapeutics* 23.2 (2006): 247-253.
- 69) Ruszczyński, M., A. Radzikowski, and H. Szajewska. "Clinical trial: effectiveness of *Lactobacillus rhamnosus* (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children." *Alimentary pharmacology & therapeutics* 28.1 (2008): 154-161.
- 70) Wu, Yi-Jie, et al. "Evaluation of efficacy and safety of *Lactobacillus rhamnosus* in children aged 4–48 months with atopic dermatitis: An 8-week, double-blind, randomized, placebo-controlled study." *Journal of Microbiology, Immunology and Infection* 50.5 (2017): 684-692.
- 71) Kalliomäki, Marko, et al. "Probiotics in primary prevention of atopic disease: a randomized placebo-controlled trial." *The Lancet* 357.9262 (2001): 1076-1079.
- 72) Kaye, Elizabeth Krall. "Daily Intake of Probiotic *Lactobacilli* May Reduce Caries Risk in Young Children." *Journal of Evidence Based Dental Practice* 17.3 (2017): 284-286.
- 73) Sinn, Dong Hyun, et al. "Therapeutic effect of *Lactobacillus acidophilus*-SDC 2012, 2013 in patients with irritable bowel syndrome." *Digestive diseases and sciences* 53.10 (2008): 2714-2718.
- 74) Gao, Xing Wang, et al. "Dose–response efficacy of a proprietary probiotic formula of *Lactobacillus acidophilus* CL1285 and *Lactobacillus casei* LBC80R for antibiotic-associated diarrhea and *Clostridium difficile*-associated diarrhea prophylaxis in adult patients." *The American journal of gastroenterology* 105.7 (2010): 1636-1641.
- 75) Ooi, L-G., et al. "*Lactobacillus acidophilus* CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters." *Journal of dairy science* 93.11 (2010): 5048-5058.
- 76) Rerksuppaphol, Sanguansak, and Lakkana Rerksuppaphol. "A randomized double-blind controlled trial of *Lactobacillus acidophilus* plus *Bifidobacterium bifidum* versus placebo in patients with hypercholesterolemia." *Journal of clinical and diagnostic research: JCDR* 9.3 (2015): KC01.
- 77) Bader J, et al. "Processing, consumption and effects of probiotic microorganisms." *Encyclopedia of Life Support Systems*. (2012).
- 78) Ishida, Y., et al. "Clinical effects of *Lactobacillus acidophilus* strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study." *Journal of Dairy Science* 88.2 (2005): 527-533.
- 79) Ishida, Yu, et al. "Effect of milk fermented with *Lactobacillus acidophilus* strain L-92 on symptoms of Japanese cedar pollen allergy: a randomized placebo-controlled trial." *Bioscience, biotechnology, and biochemistry* 69.9 (2005): 1652-1660.
- 80) Torii, Shinpei, et al. "Effects of oral administration of *Lactobacillus acidophilus* L-92 on the symptoms and serum markers of atopic dermatitis in children." *International archives of allergy and immunology* 154.3 (2011): 236-245.
- 81) Chitapanarux, Imjai, et al. "Randomized controlled trial of live *Lactobacillus acidophilus* plus *Bifidobacterium bifidum* in prophylaxis of diarrhea during radiotherapy in cervical cancer patients." *Radiation Oncology* 5.1 (2010): 31.
- 82) Niedzielin, Krzysztof, Hubert Kordecki, and Bożena Birkenfeld. "A controlled, double-blind, randomized study on the efficacy of *Lactobacillus plantarum* 299V in patients with irritable bowel syndrome." *European Journal of Gastroenterology & Hepatology* 13.10 (2001): 1143-1147. 83) Kim, H. Jae, et al. "A randomized controlled trial of a probiotic, VSL# 3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome." *Alimentary Pharmacology & Therapeutics* 17.7 (2003): 895-904.

- 84) Nobaek, Sören, et al. "Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome." *The American Journal of Gastroenterology* 95.5 (2000): 1231-1238.
- 85) Nikfar, Shekoufeh, et al. "Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials." *Diseases of the Colon & Rectum* 51.12 (2008): 1775-1780.
- 86) Ducrotté, Philippe, Prabha Sawant, and Venkataraman Jayanthi. "Clinical trial: *Lactobacillus plantarum* 299v (DSM 9843) improves symptoms of irritable bowel syndrome." *World Journal of Gastroenterology*: WJG 18.30 (2012): 4012.
- 87) Kumar, CSV Satish, et al. "Protective effect of *Lactobacillus plantarum* 21, a probiotic on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats." *International Immunopharmacology* 25.2 (2015): 504-510.
- 88) Biliboni, Rodrigo, et al. "VSL# 3 probiotic-mixture induces remission in patients with active ulcerative colitis." *The American Journal of Gastroenterology* 100.7 (2005): 1539-1546.
- 89) Han, Youngshin, et al. "A randomized trial of *Lactobacillus plantarum* CJP133 for the treatment of atopic dermatitis." *Pediatric Allergy and Immunology* 23.7 (2012): 667-673.
- 90) Mane, J., et al. "A mixture of *Lactobacillus plantarum* CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial." *Nutricion Hospitalaria* 26.1 (2011).
- 91) Lönnemark, Elisabet, et al. "Intake of *Lactobacillus plantarum* reduces certain gastrointestinal symptoms during treatment with antibiotics." *Journal of Clinical Gastroenterology* 44.2 (2010): 106-112.
- 92) Naruszewicz, Marek, et al. "Effect of *Lactobacillus plantarum* 299v on cardiovascular disease risk factors in smokers." *The American Journal of Clinical Nutrition* 76.6 (2002): 1249-1255.
- 93) Costabile, Adele, et al. "An in vivo assessment of the cholesterol-lowering efficacy of *Lactobacillus plantarum* ECGC 13110402 in normal to mildly hypercholesterolaemic adults." *PLoS One* 12.12 (2017): e0187964.
- 94) Roškar, Irena, et al. "Effects of a probiotic product containing *Bifidobacterium animalis* subsp. *animalis* IM386 and *Lactobacillus plantarum* MP2026 in lactose intolerant individuals: Randomized, placebo-controlled clinical trial." *Journal of Functional Foods* 35 (2017): 1-8.
- 95) Strus, Magdalena, et al. "Studies on the effects of probiotic *Lactobacillus* mixture given orally on vaginal and rectal colonization and on parameters of vaginal health in women with intermediate vaginal flora." *European Journal of Obstetrics & Gynecology and Reproductive Biology* 163.2 (2012): 210-215.
- 96) Michalickova, Danica M., et al. "*Lactobacillus helveticus* Lafti L10 Supplementation Modulates Mucosal and Humoral Immunity in Elite Athletes: A Randomized, Double-Blind, Placebo-Controlled Trial." *The Journal of Strength & Conditioning Research* 31.1 (2017): 62-70.
- 97) Liang, S., et al. "Administration of *Lactobacillus helveticus* NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress." *Neuroscience* 310 (2015): 561-577.
- 98) Chung, Young-Chul, et al. "Fermented milk of *Lactobacillus helveticus* IDCC3801 improves cognitive functioning during cognitive fatigue tests in healthy older adults." *Journal of Functional Foods* 10 (2014): 465-474.
- 99) Jauhainen, Tiina, et al. "*Lactobacillus helveticus* fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement." *American Journal of Hypertension* 18.12 (2005): 1600-1605.
- 100) Narva, Mirikka, et al. "Effects of long-term intervention with *Lactobacillus helveticus*-fermented milk on bone mineral density and bone mineral content in growing rats." *Annals of Nutrition and Metabolism* 48.4 (2004): 228-234.
- 101) Narva, Mirikka, et al. "The effect of *Lactobacillus helveticus* fermented milk on acute changes in calcium metabolism in postmenopausal women." *European journal of nutrition* 43.2 (2004): 61-68.
- 102) Taverniti, Valentina, and Simone Guglielmetti. "Health-promoting properties of *Lactobacillus helveticus*." *Frontiers in Microbiology* 3 (2012).
- 103) Rizzardini, Giuliano, et al. "Evaluation of the immune benefits of two probiotic strains *Bifidobacterium animalis* ssp. *lactis*, BB-12<sup>®</sup> and *Lactobacillus paracasei* ssp. *paracasei*, L. casei 431<sup>®</sup> in an influenza vaccination model: a randomised, double-blind, placebo-controlled study." *British Journal of Nutrition* 107.6 (2012): 876-884.
- 104) Riezzo, G., et al. "Randomised clinical trial: efficacy of *Lactobacillus paracasei*-enriched artichokes in the treatment of patients with functional constipation—a double-blind, controlled, crossover study." *Alimentary Pharmacology & Therapeutics* 35.4 (2012): 441-450.
- 105) Costa, D. J., et al. "Efficacy and safety of the probiotic *Lactobacillus paracasei* LP-33 in allergic rhinitis: a double-blind, randomized, placebo-controlled trial (GA2LEN Study)." *European Journal of Clinical Nutrition* 68.5 (2014): 602-607.
- 106) Bendali, Farida, Nassim Madi, and Djamilia Sadoun. "Beneficial effects of a strain of *Lactobacillus paracasei* subsp. *paracasei* in *Staphylococcus aureus*-induced intestinal and colonic injury." *International Journal of Infectious Diseases* 15.11 (2011): e787-e794.
- 107) Tsai, Yueh-Ting, Po-Ching Cheng, and Tzu-Ming Pan. "Immunomodulating activity of *paracasei* subsp. *paracasei* NTU 101 in enterohemorrhagic *Escherichia coli* O157H7-infected mice." *Journal of Agricultural and Food Chemistry* 58.21 (2010): 11265-11272.
- 108) Jankowska, Alicja, et al. "Competition of *Lactobacillus paracasei* with *Salmonella enterica* for adhesion to Caco-2 cells." *BioMed Research International* 2008 (2008).
- 109) Passariello, A., et al. "Randomised clinical trial: efficacy of a new synbiotic formulation containing *Lactobacillus paracasei* B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea." *Alimentary Pharmacology & Therapeutics* 35.7 (2012): 782-788.
- 110) Sullivan, Åsa, Carl E. Nord, and Birgitta Evengård. "Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome." *Nutrition Journal* 8.1 (2009): 4.
- 111) Institute of Food Technologists (IFT). "What are fructooligosaccharides and how do they provide digestive, immunity and bone health benefits?" *ScienceDaily* (2013).
- 112) Gibson, Glenn R. "Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin." *The Journal of nutrition* 129.7 (1999): 1438S-1441S.
- 113) Flamm, Gary, et al. "Inulin and oligofructose as dietary fiber: a review of the evidence." *Critical reviews in food science and nutrition* 41.5 (2001): 353-362.
- 114) Cardarelli, Haïssa R., et al. "Inulin and oligofructose improve sensory quality and increase the probiotic viable count in potentially synbiotic petit-suisse cheese." *LWT-Food Science and Technology* 41.6 (2008): 1037-1046.
- 115) Robinson, Ramona R., Joellen Feirtag, and Joanne L. Slavin. "Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects." *Journal of the American College of Nutrition* 20.4 (2001): 279-285.
- 116) Gibson, Glenn R. "Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin." *The Journal of nutrition* 129.7 (1999): 1438S-1441S.
- 117) Flamm, Gary, et al. "Inulin and oligofructose as dietary fiber: a review of the evidence." *Critical reviews in food science and nutrition* 41.5 (2001): 353-362.
- 118) Van Loo, Jan, et al. "On the presence of inulin and oligofructose as natural ingredients in the western diet." *Critical Reviews in Food Science & Nutrition* 35.6 (1995): 525-552.
- 119) Niness, Kathy R. "Inulin and oligofructose: what are they?" *The Journal of nutrition* 129.7 (1999): 1402S-1406S.
- 120) Rao, A. V. "Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects." *The Journal of nutrition* 129.7 (1999): 1442S-1445S.